SHP2 is a protein tyrosine phosphatase encoded by the PTPN11 gene. SHP2 mediates growth factor and cytokine signaling. Gain-of-function SHP2 mutations are causally associated with leukemias. The wildtype SHP2 is critical for tumor growth of several types of carcinoma. In the last few years, we have been trying to discover and optimize novel inhibitors targeting SHP2.  These will be discussed in the presentation.

Biography
Dr. Jerry Wu received his B.S. degree in 1982 from Xiamen University and his Ph.D. degree in 1988 from the University of Kansas Medical Center. After postdoctoral trainings at Memorial Sloan-Kettering Cancer Cener and the University of Virgina, he established his laboratory in H. Lee Moffitt Cancer Center and Research Institute at the Univeristy of South Florida. Currently, Dr. Wu is a Senior Member of the Moffitt Cancer Center and a Full Professor of the University of South Florida. His research interests include cell signaling and targeted therapy. He has authored over 70 peer-reviewed articles. Dr. Wu has served on several federal grant review panels of National Institutes of Health, U.S Department of Veterans Affairs, and the Department of Defense.

Host: Dr. Qi Zeng